Study Evaluating Effects of Multiple-Dose Administration of Itraconazole on the Single Dose Pharmacokinetics of Conjugated Estrogens/Bazedoxifene in Non-Obese and Obese Postmenopausal Women
Last updated on April 2022Recruitment
- Recruitment Status
- Completed
Inclusion Criteria
- Generally healthy postmenopausal women, aged 40-64. Intact Uterus
- Generally healthy postmenopausal women, aged 40-64. Intact Uterus
Exclusion Criteria
- The use of oral, vaginal, or transdermal estrogen, androgen or progestin-containing medications within 30 days before study drug administration.
- The use of oral, vaginal, or transdermal estrogen, androgen or progestin-containing medications within 30 days before study drug administration.
Summary
- Conditions
- Healthy
- Type
- Interventional
- Phase
- Phase 1
- Design
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Basic Science
Participation Requirements
- Age
- Between 40 years and 64 years
- Gender
- Only females
Inclusion Criteria
- Generally healthy postmenopausal women, aged 40-64. Intact Uterus
- Generally healthy postmenopausal women, aged 40-64. Intact Uterus
Exclusion Criteria
- The use of oral, vaginal, or transdermal estrogen, androgen or progestin-containing medications within 30 days before study drug administration.
- The use of oral, vaginal, or transdermal estrogen, androgen or progestin-containing medications within 30 days before study drug administration.
Tracking Information
- NCT #
- NCT02100553
- Collaborators
- Not Provided
- Investigators
- Study Director: Pfizer CT.gov Call Center Pfizer
Get Well Soon